More
    Guided Solutions - Connecting Talent With Innovation/div>

    Anuncia announces first successful implant of ReFlow mini flusher in hydrocephalus patient

    Anuncia Medical has announced the successful first implant of the company’s US Food and Drug Administration (FDA)-cleared ReFlow mini flusher device. Performed on by neurosurgeon Samuel...

    HAPPE Spine Announces First Clinical Use of the INTEGRATE®-C Interbody Fusion System

    HAPPE Spine announces that the first clinical case with the INTEGRATE®-C Interbody Fusion System was completed by co-inventor and neurosurgeon Dr. Stephen Smith, MD, at the...

    DermaSensor reports positive results for skin cancer detection device across multiple skin tones

    DermaSensor announced promising results from a sub-analysis study focusing on skin cancer detection across different skin tones. The sub-analysis came from the company’s DERM-SUCCESS study, which previously...

    Intuitive’s Ion Endoluminal System Used for First Time in the UK

    Clinicians at Royal Brompton Hospital, part of Guy’s and St Thomas’ NHS Foundation Trust, and St Bartholomew’s Hospital are the first in the UK...

    Feasibility study backs Glucotrack implantable CGM

    Glucotrack (Nasdaq:GCK) announced that it completed a feasibility study for its implantable continuous glucose monitor (CGM). Rutherford, New Jersey-based Glucotrack designed its CGM for patients with...

    Suono Bio Reports Encouraging Results From a First in Human (FiH) Study of Its Ultrasound Mediated Drug Delivery Platform

    Suono Bio Inc., the company revolutionizing therapeutic platforms to improve the efficacy and safety of novel medicines, has released encouraging results from the first...

    Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease

    White matter plays a critical role in brain function and reducing white matter atrophy and myelin loss may contribute to slowing Alzheimer’s disease progression. Early...

    Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure

    US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"),...

    Study backs Lunit’s AI-powered cancer diagnostics

    Lunit recently announced the results of its study demonstrating the effectiveness of artificial intelligence (AI) solutions in cancer diagnostics. The study, published in the journal Radiology,...

    Latest articles